U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes (NYSE:LLY)

Only prescription medication in U.S. to combine the dual mechanisms of action of SGLT2 and DPP-4 inhibitors to improve glycemic control as an adjunct to diet and exercise
As an add-on to metformin, GLYXAMBI was superior in reducing A1C when compared with either empagliflozin or linagliptin alone

U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes (NYSE:LLY)